Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Significant Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 24,054,644 shares, a growth of 111.8% from the January 15th total of 11,356,718 shares. Based on an average trading volume of 21,191,388 shares, the days-to-cover ratio is presently 1.1 days. Currently, 17.5% of the company’s shares are sold short. Currently, 17.5% of the company’s shares are sold short. Based on an average trading volume of 21,191,388 shares, the days-to-cover ratio is presently 1.1 days.

Plus Therapeutics Trading Up 7.1%

PSTV opened at $0.28 on Friday. The stock has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.52. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The firm has a market cap of $38.22 million, a price-to-earnings ratio of -0.14 and a beta of 0.89.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PSTV shares. Zacks Research downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. Lake Street Capital started coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $1.00 price target (down previously from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Finally, Ascendiant Capital Markets dropped their price objective on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.80.

Institutional Trading of Plus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. L1 Global Manager Pty Ltd acquired a new stake in shares of Plus Therapeutics during the fourth quarter worth about $1,167,000. Altium Capital Management LLC purchased a new position in Plus Therapeutics in the third quarter worth $628,000. State Street Corp boosted its stake in shares of Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in Plus Therapeutics during the fourth quarter worth $525,000. Finally, Geode Capital Management LLC grew its stake in Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after acquiring an additional 589,544 shares during the last quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.